This cohort study compares the effectiveness and safety of the 3 most widely prescribed long-acting muscarinic antagonist–long-acting β2-agonists (LAMA-LABA) regimens in the US that may support more informed chronic obstructive pulmonary disease treatment decisions, with implications for both clinical management and environmental stewardship.
JAMA Internal Medicine published a clinical update in Research Highlights on 01 Apr 2026.
The item focuses on Effectiveness and Safety of LAMA-LABA Inhalers in COPD.
Review the original article for the full source wording and details.